Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On February 15, 2022, the Board of Directors of Adamis Pharmaceuticals Corporation (the "Company") approved amendments to the Company's Code of Business Conduct and Ethics (the "Code"). The amendments were intended to improve language, appearance and style, remove certain provisions regarding workplace matters that the Company believes are more appropriately covered in its other employment policies, and otherwise enhance the guidance for employees, officers and directors on matters relating to compliance with laws, conflicts of interests, disclosure and compliance, compliance with the Code, and other matters. Additionally, the amendments to the Code included a number of technical, administrative or non-substantive changes. The amendments did not result in any waiver, explicit or implicit, of any provision of the Code.

The foregoing description of the amended Code does not purpose to be complete and is qualified in its entirety by reference to the Code, attached as Exhibit 14.1 hereto and incorporated herein by reference.

© Edgar Online, source Glimpses